Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Lymphocytic Leukemia, Chronic Clinical Trials

A listing of Lymphocytic Leukemia, Chronic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (58) clinical trials

Acalabrutinib in Patients With Relapsed/Refractory and Treatment na ve Deletion 17p CLL/SLL

To investigate the safety and efficacy of acalabrutinib for patients with CLL/SLL that have relapsed/refractory disease or treatment naive deletion 17p.

Phase

Nivolumab With Ibrutinib for Relapsed Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Study Groups and Study Drug Administration: If you are found to be eligible to take part in this study, you will be assigned to 1 of 2 study groups, depending on if you are already taking ibrutinib or not. If you are NOT already taking ibrutinib, you will be assigned ...

Phase

First-line Therapy With Ibrutinib Fludarabine Cyclophosphamide and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)

Study Drug Administration: Each study cycle is 4 weeks (28 days). If you are found to be eligible to take part in this study, you will receive the study drug combination on the following schedule during Cycles 1-3: You will receive obinutuzumab by vein over 4-6 hours on the following ...

Phase

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Current protocols use G-CSF to mobilize hematopoietic progenitor cells from matched sibling and volunteer unrelated donors. Unfortunately, this process requires four to six days of G-CSF injection and can be associated with side effects, most notably bone pain and rarely splenic rupture. BL-8040 is given as a single SC injection, ...

Phase

Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)

The purpose of this study is to evaluate the clinical safety and efficacy of MOR00208 combined with idelalisib or venetoclax. The study will include safety run-in phase for each cohort with an evaluation of the safety data. This evaluation will be done by an Independent Data Monitoring Committee.

Phase

An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

This is a multi-center, open-label, study to evaluate the safety and efficacy of ublituximab (TG-1101) in combination with TGR-1202 for patients who have progressed on treatment arms previously enrolled in Protocol UTX-TGR-304

Phase

A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant

This is a multicenter prospective randomized phase IIa/IIb clinical trial designed to determine the MTD (Maximum Tolerated Dose) of CD24Fc for acute GVHD (Graft Versus Host Disease) prophylaxis.

Phase

Phase II Trial GA101 Inbrutinib B CLL

Phase II study testing chemo-free induction therapy with Ibrutinib + Obinutuzumab during nine months followed by a MRD-driven strategy. Assessment of response as well as bone marrow MRD evaluation will be performed at Day 1 month 9: 1. Patients reaching CR with marrow MRD below 10-4 threshold will continue ibrutinib ...

Phase

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Phase

Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

This is a Phase 2, open-label, study of TGR-1202, a PI3K delta inhibitor, administered as a single agent in Chronic Lymphocytic Leukemia (CLL) patients who are intolerant to prior BTK inhibitors (ibrutinib, other) or prior PI3K delta inhibitors (idelalisib, other)

Phase